How significant is the ₹126.54 lakh revenue figure?

It is the first revenue Rekvina has ever reported, marking the start of commercial operations. The scale is tiny, however, and less than the annual loss.

Is the company profitable now?

No. Despite starting sales, Rekvina posted a net loss of ₹25.47 lakhs for FY26. Revenue did not cover its costs.

What is the state of the balance sheet?

Net worth is negative at -₹122.82 lakhs, meaning liabilities exceed assets. The equity base is wiped out by accumulated losses.

Earnings · Pharmaceuticals · Micro cap

Rekvina posts its first-ever revenue. The losses continue.

The nano-cap reported ₹126.54 lakhs in sales for FY26, its first commercial revenue, but stayed in the red with a net loss of ₹25.47 lakhs.

— 1 earlier story on Rekvina Laboratories Ltd. →

REKVINA LAB. By Tipsheet Editorial 21 May 2026 · 8:25 PM IST Verify on BSE · NSE

Mkt cap₹21.4 cr

ROE41.27%

₹126.54 lakhs First-ever revenue for Rekvina in FY26.

What's new

Rekvina generated its first-ever revenue of ₹126.54 lakhs in FY26, up from nil in FY25.
The company posted a net loss of ₹25.47 lakhs for the year.
Net worth remained deeply negative at -₹122.82 lakhs.

Why this matters

The first sale is a milestone for a pre-revenue company, but the amount is trivial. The losses exceed revenue, and the balance sheet remains underwater. No new strategic details on the Radiant Parenterals acquisition were added.

What we're watching

Whether revenue scales from this low base in coming quarters.
Progress on funding the Radiant Parenterals acquisition.
Any steps to address the -₹122.82 lakh net worth.

The full read

Rekvina Laboratories reported its first-ever revenue: ₹126.54 lakhs in FY26, up from nil a year earlier. A milestone. The company still lost ₹25.47 lakhs for the year, and its net worth sits at -₹122.82 lakhs. The revenue does not yet cover the cost of being a public company, let alone the losses. The filing repeats earlier announcements about the Radiant Parenterals acquisition and preferential share issuances, adding nothing new. For a nano-cap trading on thin expectations, the headline is the first rupee of sales, not the strategy. Hardly.

Questions answered

How significant is the ₹126.54 lakh revenue figure?: It is the first revenue Rekvina has ever reported, marking the start of commercial operations. The scale is tiny, however, and less than the annual loss.
Is the company profitable now?: No. Despite starting sales, Rekvina posted a net loss of ₹25.47 lakhs for FY26. Revenue did not cover its costs.
What is the state of the balance sheet?: Net worth is negative at -₹122.82 lakhs, meaning liabilities exceed assets. The equity base is wiped out by accumulated losses.
Are there any new strategic updates?: No. The filing repeats earlier announcements about the Radiant Parenterals acquisition and preferential share issuances, adding no new details or timelines.

Mentioned: ₹126.54 lakhs revenue (FY26) · -₹122.82 lakhs net worth · Radiant Parenterals acquisition

Primary source BSE · NSE · Tijori

An independent reading of the company's own disclosure — the primary filing above is the final word.

Company snapshot

Rekvina Laboratories Ltd.

Pharmaceuticals

₹22 cr

Latest quarter · Mar 2026

Sales₹1 cr

Net profit−₹0 cr

Op. margin−8.3%

EPS−₹0.10

Strength & growth

Debt / equity-0.74×

Current ratio0.09×

Sales CAGR+35.0%

Story so far

All notes on REKVINA LAB. →

21 May 2026 · 8:25 PM IST Rekvina posts its first-ever revenue. The losses continue.
61d ago Rekvina Laboratories generates its first revenue as losses persist